Pathalys
Research Triangle Park, US · Founded 2021 · 18 employees on LinkedIn · 7 known investors
Pathalys Pharma is a private biopharmaceutical company developing treatments for kidney disease, including upacicalcet, which is in late-stage development. The company is working toward an NDA submission and pre-commercialization efforts.
Investors · 7
Catalys PacificTokyo
OrbiMedNew York · $1M – $75M
Samsara BioCapitalPalo Alto
AbingworthreportedLondon · $15M – $30M
KB InvestmentreportedSeoul · $743K – $40M
Also in the syndicate · 2
J.P. Morgan Life Sciences Private CapitalTCGXlead
Funding
SEC filings, press & company announcements- Undisclosed amountseries BAug 2024
TCGX (lead), J.P. Morgan Life Sciences Private Capital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Pathalys do?
- Pathalys Pharma is a private biopharmaceutical company developing treatments for kidney disease, including upacicalcet, which is in late-stage development. The company is working toward an NDA submission and pre-commercialization efforts.
- Who are Pathalys's investors?
- Pathalys's investors include Catalys Pacific, OrbiMed, Samsara BioCapital, Abingworth, KB Investment.
- Where is Pathalys headquartered?
- Pathalys is headquartered in Research Triangle Park, US.

